Junshi Biosciences and Dr. Reddy's Partner to Develop Toripalimab in 21 Countries.

08 May 2023 | Monday | News

Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences”, HKEX: 1877; SSE: 688180) announced a collaboration with Dr. Reddy’s Laboratories Limited (“Dr. Reddy’s”) to develop and commercialize toripalimab, the anti-PD-1 monoclonal antibody in Latin America, India, South Africa, and at the election of Dr. Reddy’s, also in Australia, New Zealand and other countries.
Image Source | Public Domain

Image Source | Public Domain

“We are thrilled to have established a partnership with Dr. Reddy’s while toripalimab’s global commercial network has been steadily expanding, reaching more than 50 countries and advancing our mission of being ‘In China, For Global,’” said Dr. Ning LI, Chief Executive Officer of Junshi Biosciences. “Dr. Reddy’s is a well-respected global pharmaceutical company and extends its business over nearly 70 countries worldwide, achieving impressive commerical presence across the globe. We hope that in the near future, leveraging Dr. Reddy’s partnership and strong presence, our innovative medicines can accelerate access to new geographies and deliver better and more affordable treatment options to even more patients.”

M.V. Ramana, CEO – Branded Markets (India & Emerging Markets), Dr. Reddy’s said, “We are pleased to partner with Junshi Biosciences to take this important product to more patients. Oncology is a focus area for Dr. Reddy’s. This partnership is a further step towards increasing our offerings to patients in oncology as we aim to build a robust and comprehensive portfolio in the segment. We are committed to facilitating access to innovative products as we pursue our goal of serving over 1.5 billion patients by 2030.”

Under the license and commercialization agreement, Junshi Biosciences will grant a licence to Dr. Reddy’s to develop and exclusively commercialize toripalimab in Brazil, Mexico, Colombia, Argentina, Peru, Chile, Panama, Uruguay, India and South Africa1. Dr. Reddy’s may elect to expand the scope of the license to cover Australia, New Zealand and nine other countries2.

Under the terms of the agreement, Junshi Biosciences also grants Dr. Reddy’s the exclusive right of first negotiation for commercialization, in the event that Junshi Biosciences determines to grant any third party the rights to commercialize two other products as agreed in the agreement in one or more countries within the total 21 countries of Dr. Reddy’s Territory3.

Junshi Biosciences may receive up to an aggregate of US$728.3 million for upfront payment, potential expansion of Dr. Reddy’s Territory and milestone payment, plus double-digit percentage of royalties on the net sales of products containing toripalimab.

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2024 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close